Azad Bonni
A5065674854- Alzheimer's disease research and treatments
- Parkinson's Disease Mechanisms and Treatments
- Dementia and Cognitive Impairment Research
- Synthetic Organic Chemistry Methods
- Tryptophan and brain disorders
- Neurogenetic and Muscular Disorders Research
- Amyotrophic Lateral Sclerosis Research
- Cholinesterase and Neurodegenerative Diseases
Roche (Switzerland)
2022-2025
Roche (Sweden)
2024
Amyloid-plaque removal by monoclonal antibody therapies slows clinical progression in symptomatic Alzheimer's disease; however, the potential for delaying onset of symptoms asymptomatic people is unknown. The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) an ongoing platform trial assessing safety and efficacy multiple investigational products participants with dominantly inherited disease (DIAD) caused mutations. On basis findings amyloid downstream biological effects from...
Astrocyte-specific ion pump α2-Na + /K -ATPase plays a critical role in the pathogenesis of amyotrophic lateral sclerosis (ALS). Here, we test effect Atp1a2 mRNA-specific antisense oligonucleotides (ASOs) to induce knockdown widely used ALS animal model, SOD1*G93A mice. Two ASOs led efficient and significantly reduced SOD1 aggregation vivo . Although ASO-treated mice displayed no off-target or systemic toxicity, exhibited an accelerated disease onset shorter lifespan than control...
Aims To describe the design and baseline data of PASADENA study Methods Prasinezumab is a humanized IgG1 monoclonal antibody, which selectively binds aggregated α-synuclein, potentially reducing neuronal toxicity slowing disease progression. This Phase 2 multicentre, randomised, double-blind, placebo-controlled evaluated safety efficacy 4 weekly intravenous prasinezumab, at high dose (4500 mg/3500 mg body weight ≥65 kg/<65 kg) or low (1500 mg), versus placebo in patients with early...